Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Phase 3 failures

Allergan logo

More waiting for Allergan and Gedeon Richter’s antipsychotic

FDA announced it will take another three months to review cariprazine for schizophrenia

- PMLiVE

Kythera bags FDA approval for double chin therapy

Comes as cosmetics industry sees major growth

- PMLiVE

Actavis completes $70.5bn Allergan acquisition

Finalisation comes after bidding war with deal-hungry Valeant

- PMLiVE

NICE recommends Ozurdex for diabetic eye condition

Draft guidance cites implant as option for patients with diabetic macular oedema

- PMLiVE

Actavis to buy Allergan for $66bn

Ends Valeant’s pursuit of Botox maker

- PMLiVE

Allergan ‘close’ to $60bn takeover agreement with Actavis

If successful the negotiations would scupper Valeant's hostile bid

- PMLiVE

Actavis ‘considering’ white knight bid for Allergan

Wall Street Journal says Irish pharma company set to challenge Valeant's bid

- PMLiVE

Valeant dangles higher bid in front of Allergan shareholders

Proposes $200 a share deal

- PMLiVE

Valeant adds Jeffrey Ubben to board

CEO of ValueAct supports takeover of Allergan

- PMLiVE

Lundbeck launches Brintellix in first EU market

The antidepressant set to sell worldwide

- PMLiVE

Pharma and med tech companies form eye health group

The Industry Vision Group wants the NHS to make eye care a priority

- PMLiVE

New eye indication for Allergan’s Ozurdex

EU approval extends the drug's use to diabetic macular oedema

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links